[1] WARKENTIN T E,LEVINE M N,HIRSH J,et al.Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin[J].New Eng J Med,1995,332(20): 1330-1335.
[2] GREINACHER A,FARNER B,KROLL H,et al.Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis.A retrospective analysis of 408 patients[J].Thromb Haemost,2005,94: 132-135.
[3] WARKENTIN T E,KELTON J G.A 14-year study of heparin-induced thrombocytopenia[J].Am J Med,1996,101: 502-507.
[4] LEWIS B E,WALLIS D E,LEYA F,et al.Argatroban anticoagulation in patients with heparin-induced thrombocytopenia[J].Arch Intern Med,2003,163: 1849-1856.
[5] BAN-HOEFEN M,FRANCIS C.Heparin induced thrombocytopenia and thrombosis in a tertiary care hospital[J].Thromb Res,2009,124: 189-192.
[6] WARKENTIN T E,KELTON J G.Temporal aspects of heparin-induced thrombocytopenia[J].New Eng J Med,2001,344(17): 1286-1292.
[7] JONES C J,BENI S,LIMTIACO J,et al.Heparin characterization: challenges and solutions[J].Annu Rev Ana Chem,2011,4: 439-465
[8] ZUCKER M B,KATZ I R.Platelet factor 4: production,structure,and physiologic and immunologic action[J].Proc Soc Exp Biol Med,1991,198: 693-702.
[9] SUVARNA S,ESPINASSE B,QI R,et al.Determinants of PF4/heparin immunogenicity[J].Blood,2007,110: 4253-4260.
[10] WARKENTIN T E,SHEPPARD J A,MOORE J C,et al.Studies of the immune response in heparin-induced thrombocytopenia[J].Blood,2009,113(20): 4963-4969.
[11] KELTON J G,SHERIDAN D,SANTOS A,et al.Heparin-induced thrombocytopenia: laboratory studies[J].Blood,1988,72: 925-930.
[12] HUGHES M,HAYWARD C P,WARKENTIN T E,et al.Morphological analysis of microparticle generation in heparin-induced thrombocytopenia[J].Blood,2000,96: 188-194.
[13] ZHENG Y,YU M,PODD A,et al.Critical role for mouse marginal zone B cells in PF4/heparin antibody production[J].Blood,2013,121: 3484-3492.
[14] GREINACHER A,KOHLMANN T,STROBEL U,et al.The temporal profile of the anti-PF4/heparin immune response[J].Blood,2009,113(20): 4970-4976.
[15] SUH J S,MALIK M I,ASTER R H,et al.Characterization of the humoral immune responsein heparin-induced thrombocytopenia[J].Am J Hematol,1997,54(3): 196-201.
[16] MARTIN F,KEARNEY J F.B1 cells: similarities and differences with other B cell subsets[J].Curr Opin Immunol,2001,13(2): 195-201.
[17] MARTIN F,KEARNEY J F.Marginal-zone B cells[J].Nat Rev Immunol,2002,2(5): 323-335.
[18] GRAY D,MACLENNAN I C,BAZIN H,et al.Migrant mu+delta+and static mu+delta-B lymphocyte subsets[J].Eur J Immunol,1982,12(7): 564-569.
[19] OLIVER A M,MARTIN F,KEARNEY J F.IgMhighCD21high lymphocytes enriched in thesplenic marginal zone generate effector cellsmore rapidly than the bulk of follicular B cells[J].J Immunol,1999,162(12): 7198-7207.
[20] MARTIN F,OLIVER A M,KEARNEY J F.Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens[J].Immunity,2001,14(5): 617-629.
[21] GUINAMARD R,OKIGAKI M,SCHLESSINGER J,et al.Absence of marginal zone B cellsin Pyk-2-deficient mice defines their role in the humoral response[J].Nat Immunol,2000,1(1): 31-36.
[22] HERZENBERG L A.B-1 cells: the lineage question revisited[J].Immunol Rev,2000,175: 9-22.
[23] SUVARNA S,QI R,AREPALLY G M.Optimization of a murine immunization model for study of PF4/heparin antibodies[J].J Thromb Haemost,2009,7(5): 857-864.
[24] SAITO T,CHIBA S,ICHIKAWA M,et al.Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development[J].Immunity,2003,18(5): 675-685.
[25] HEALY J,GOODNOW C.Positive versus negative signaling by lymphocyte antigen receptors[J].Annu Rev Immunol,1998,16: 645-670.
[26] von BOEHMER H,MELCHERS F.Checkpoints in lymphocyte development and autoimmune disease[J].Nat Immunol,2010,11(1): 14-20.
[27] MERRELL K T,BENSCHOP R J,GAULD S B,et al.Identification of anergic B cells within a wild-type repertoire[J].Immunity,2006,25(6): 953-962.
[28] GAULD S B,BENSCHOP R J,MERRELL K T,et al.Maintenance of B cell anergyrequires constant antigen receptor occupancy and signaling[J].Nat Immunol,2005,6(11): 1160-1167.
[29] BERLAND R,FERNANDEZ L,KARI E,et al.Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice[J].Immunity,2006,25(3): 429-440.
[30] LEADBETTER E A,RIFKIN I R,HOHLBAUM A M,et al.Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors[J].Nature,2002,416(6881): 603-607.
[31] VISENTIN G P,MOGHADDAM M,BEERY S E,et al.Heparin is notrequired for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis[J].J Lab Clin Med,2001,138(1): 22-31.
[32] JAAX M E,KRAUEL K,MARSCHALL T,et al.Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4[J].Blood,2013,122(2): 272-281.
[33] ZHENG Y,WANG A W,YU M,et al.B-cell tolerance regulates production of antibodiescausing heparin-induced thrombocytopenia[J].Blood,2014,123(6): 931-934.
[34] MECKLENBRAUKER I,SAIJO K,ZHENG N Y,et al.Protein kinase C delta controls self-antigen-induced B-cell tolerance[J].Nature,2002,416(6883): 860-865.
[35] MIYAMOTO A,NAKAYAMA K,IMAKI H,et al.Increased proliferation of B cells and auto-immunity in mice lacking protein kinase C delta[J].Nature,2002,416(6883): 865-869.
[36] KUEHN H S,NIEMELA J E,RANGEL-SANTOS A,et al.Loss-of-function of the protein kinase C delta(PKC delta)causes a B-cell lymphoproliferative syndrome in humans[J].Blood,2013,121(16): 3117-3125.
[37] KRAUEL K,PÖTSCHKE C,WEBER C,et al.Platelet factor 4 binds to bacteria,inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia[J].Blood,2011,117(4): 1370-1378.
[38] AREPALLY G M,HURSTING M J.Platelet factor 4/heparin antibody(IgG/M/A)in healthy subjects: a literature analysis of commercial immunoassay results[J].J Thromb Thrombolysis,2008,26(1): 55-61.
[39] WARKENTIN T E,SHEPPARD J I,MOORE J C,et al.Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays[J].J Thromb Haemost,2008,6(8): 1304-1312. |
